Zhi Tong Cai Jing·2026-02-05 02:54Core Viewpoint - The company Nocera Biopharma (09969) has seen a significant increase in stock price following the release of its earnings forecast, projecting substantial revenue growth and a return to profitability by 2025 [1] Financial Performance - Nocera Biopharma expects to achieve revenue of 2.37 billion yuan in 2025, representing a year-on-year increase of approximately 134% [1] - The company anticipates a net profit attributable to shareholders of around 630 million yuan in 2025, marking its first return to profitability [1] Product Development - The core product, Orelabrutinib, is expected to contribute significantly to revenue growth [1] - The approval of Tansimertinib in May 2025 is anticipated to further diversify the company's revenue sources [1] Clinical Trials - Nocera Biopharma has completed patient enrollment for its Phase III clinical trial of the novel TYK2 inhibitor ICP-488 for the treatment of psoriasis, with a total of 383 patients enrolled [1] - This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of ICP-488 as a monotherapy for adult patients with moderate to severe plaque psoriasis [1]